Next Article in Journal
Fused Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticancer Agents
Previous Article in Journal
Equilibrium and Release Properties of Aqueous Dispersions of Non-Steroidal Anti-Inflammatory Drugs Complexed with Polyelectrolyte Eudragit E 100
Article Menu

Article Versions

Export Article

Open AccessReview
Sci. Pharm. 2012, 80(3), 497-508; doi:10.3797/scipharm.1205-01

Development of Antimetastatic Drugs by Targeting Tumor Sialic Acids

1
School of Life Sciences, Shanghai University, Shanghai 200444, China
2
College of Science, Shanghai University, Shanghai 200444, China
*
Author to whom correspondence should be addressed.
Received: 3 May 2012 / Accepted: 18 June 2012 / Published: 18 June 2012
Download PDF [233 KB, uploaded 30 September 2016]

Abstract

One-third of all cancer categories in clinics have a high incidence of neoplasm metastasis. Neoplasm metastasis is one of the leading causes of cancer deaths. However, the prevailing therapeutic approach to this pathogenic process is presently unsatisfactory. Paradoxically to our efforts and expectations, except for some antibodies, no obvious improvements and therapeutic benefits in currently used drugs have been achieved until now. Therapeutic benefits in late-stage or elderly cancer patients are especially poor and useless. One of the reasons for this, we would guess, is the lack of therapeutic targets specifically related to neoplasm metastasis. In order to enhance the therapeutic efficacy, the development of antimetastatic drugs transcending from current drug-screening pathways is urgently needed. Antimetastatic drugs targeting aberrantly sialylated in tumors have evolved for about a quarter of a century and might be a future therapeutic option other than the currently utilized antimetastatic drugs, such as antivascular and MMP inhibitors. Since neoplasm tissues often manifest high levels of sialic acids and sialyl antigens or glycoligands, some types of sialic acid analogue, such as N-glycolylneuraminic acid (Nau5Gc), occurred in most tumor tissues which is normally absent in most humans. Consequently, more attention is needed to work with new therapeutic approaches to target these changes. This review addresses and discusses the latest six types of therapeutic approaches targeting sialic acids in metastatic tissues.
Keywords: Sialic acid; Neuraminidic acids; Neoplasm metastases; Anticancer therapy; Neoplasm targeting; Probimane; Sialylation; Glycosylation; Cancer chemotherapy; Glycobiology; Cancer biology Sialic acid; Neuraminidic acids; Neoplasm metastases; Anticancer therapy; Neoplasm targeting; Probimane; Sialylation; Glycosylation; Cancer chemotherapy; Glycobiology; Cancer biology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

LU, D.-Y.; LU, T.-R.; WU, H.-Y. Development of Antimetastatic Drugs by Targeting Tumor Sialic Acids. Sci. Pharm. 2012, 80, 497-508.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top